Abstract
Analogues of human growth hormone-releasing hormone (1–30)-amide have been developed. All analogues have been modified in position 27 with Nle and with Gaba in position 30. Additional D-amino-acids have been inserted in the GHRH(1–30)-NH2 sequence
A-1741: Nle27, Gaba30-GH-RH (1–30)-NH2 A-495: D-Ala2, Nle27, Gaba30-GH-RH (1–30 )-NH2 A-515: D Ala2, Leu15, Nle27, Gaba30-GH-RH (1–30)-NH2 A-527: D-Ala2, D-Arg11, Leu15, Nle27, Gaba30-GH-RH (1–30)-NH2.
Our analogues were synthesized by solid phase peptide synthesis and were tested is two different in vitro systems and in rat pituitary cell cultures. A-495 and A-1741 were found to be the most active in releasing GH, however they showed different activities in the two different test systems. A-495 exhibited higher potency in the superfusion system (1.63 fold potency of the GHRH (1–29)-amide), while A-1741 evoked higher GH release from cultured pituitary cells (1.5–2.5 times higher than the GH-RH(1–44)-amide). The other analogues (A-515 and A-527) were found to be equipotent to the standard molecule. We can conclude that Nle27 and Gaba30 substitutions appeared to be a good modification in in vitro test systems, and Gaba30 substitution served as a good spacer during the synthesis, since it made the coupling of the C-terminal amino acids easier and produced quantitative coupling. In addition to the advantageous properties in the synthesis these modifications with or without D-Ala at the N-terminus increased the in vitro biological activity to 1.5–2.5 fold of the GHRH molecule. The additional substitution of Gly15 with Leu and Arg11 with D-Arg did not improve the in vitro GH-releasing activity of our analogues. A detailed in vivo investigation, which is essential for the future clinical use, hasbeen performed and written in Part II of this paper.
Similar content being viewed by others
References
Guillemin R., Brazeau P., Bohlen P., Esch F., Lingand N., Wehrenberg W.B. Growth hormone-releasing factor from a human pancreatic tumour that caused acromegaly. Science 218: 585, 1982.
Rivier J., Spiess J., Thorner M., Vale M.W. Characterization of a growth hormone-releasing factor from a pancreatic islet tumour. Nature 300: 276, 1982.
Frohman L.A., Downs T.R., Williams T.C., Heimer E.P., Pan Y.-CE., Felix A.M. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J. Clin. Invest. 78: 906, 1986.
Rafferty B., Poole S., Clarke R., D. Schulster D.R. Growth hormone-releasing factor analogue hGRF(1–29)-NH2: Immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. J. Endocrinol. 107: R5, 1985.
Pertzelan A., Keret R., Bauman B., Benzeev Z., Olsen D.B., Szöke B., Comaru-Schally A.M., Laron Z. Plasma growth hormone response to synthetic GH-RH (1–44) in 52 children and adults with growth hormone deficiency of various etiologies. Horm. Res. 22: 24, 1985.
Thorner O.M., Reschke J., Chitwood J., Rogol A.D., Furlanetto R., Rivier J., Vale W., Blizzard R.M. Acceleration of growth in two children treated with human growth hormone-releasing factor. N. Engl. J. Med. 312: 4, 1985.
Pelletier G., Petitclerc D., Lapierre H., Bernier-Cardou M., Morisset J., Gaudreau P., Couture Y., Brazeau P. Injection of synthetic human growth hormone-releasing factors in dairy cows. 1. Effect on feed intake and milk yield and composition. J. Dairy Sci. 70: 2511, 1987.
Lance V.A., Murphy W.A., Suerias-Diaz J., Coy D.H. Super-active analogs of growth hormone-releasing factor (1–29) amide. Biochem. Biophys. Res. Comm. 119: 265, 1984.
Coy D.H., Murphy W.A., Sueiraz-Diaz J., Coy E.J., Lance V.A. Structure-activity studies on the N-terminal region of growth hormone-releasing factor. J. Med. Chem. 28: 181, 1985.
Coy D.H., Murphy W.A., Lance V.A., Heiman M.L Strategies in the design of synthetic agonists and antagonists of growth hormone releasing factor. Peptides 7 (Suppl. 1):49, 1986.
Coy D.H., Murphy W.A., Lance V.A., Heiman M.L. Differential effects of N-terminal modifications on the biological potencies of growth hormone releasing factor analogues with varying chain lengths. J. Med. Chem. 30: 219, 1987.
Felix A.M., Heimer E.P., Mowles T.F., Eisenbeis H., Leung P., Lambros T.J., Ahmad M., Wang C.-T. Synthesis and biological activity of novel growth hormone-releasing factor analogs. In: Theodoropoulos D. (Ed.), Peptides 1986. Walter de Gruyter, Berlin-New York, 1987, p. 481.
Gulyas J., Bajusz S., Kovács M., Schally A.V. New methods for synthesis of potent GHRH analogs. In: Penke B. and Török A. (Eds.), Peptides, Chemistry, Biology, Interaction with Proteins. Walter de Gruyter, Berlin-New York, 1988, p. 113.
Kovács M., Gulyás J., Bajusz S., Schally A.V. An evaluation of intravenous, subcutaneous, and in vitro activity of new agmatine analogs of growth hormone-releasing hormone hGH-RH(1–29)-NH2. Life Sci. 42: 27, 1988.
Murphy W.A., Coy D.H. Potent long-acting alkylated analogs of growth hormone-releasing factor. Peptide Res. 1: 36, 1988.
Grossman A., Savage M.O., Blacklay A., Ross R.M., Plowman P.N., Preece M.A., Coy D.H., Besser G.M. The use of growth hormone-releasing hormone in the diagnosis and treatment of short stature. Horm. Res. 22: 52, 1985.
Hernandez M., Fragoso J., Barrio R., Argente J., Arilla E. Subcutaneous treatment with growth hormone-releasing hormone for short stature. Horm. Res. 30: 252, 1988.
Lapierre H., Pelletier G., Petitclerc D., Dubreuil P., Morisset J., Gaudreau P., Couture Y, Brazeau P. Effect of human growth hormone-releasing factor (1–29)-NH2 on growth hormone release and milk production in diary cows. J. Dairy Sci. 71: 92, 1988.
Scarborough R., Gulyás J., Schally A.V., Reeves J.J. Analogs of growth hormone-releasing hormone induce release of growth hormone in the bovine. J. Anim. Sci. 66: 1386, 1988.
Mezö I., Szöke B., Vadász Zs., Teplán I., Makara G.B., Kovács M., Horváth J., Flerkó B. Synthesis of a novel GRF analog. In: Jung G., Bayer E. (Eds.), Peptides, 1988. Walter de Gruyter, Berlin-New York, 1989, p. 604.
Mezö I., Szöke B., Teplán I., Makara G.B., Rappay Gy., Kovács M., Horváth J., Vigh S. Synthesis of GRF analogs with potent in vivo GH-releasing activity. In: Rivier E., Marshall G.R. (Eds.), Peptides, Chemistry, Structure and Biology. Escom, Leiden, The Netherlands, 1990, p. 231.
Stewart J.M., Young J.D. Solid phase synthesis of peptides. In: Solid phase peptide synthesis. (Pierce Chemical Company, Rockford, III.), 1984, p. 71.
Kaiser E., Colescott R.L., Bossinger CD., Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 34: 595, 1970.
Vigh S., Schally A.V. Interaction between hypothalamic peptides in a superfused pituitary cell system. Peptides 5: 241, 1984.
Makara G.B., Szendrey T., Rappay Gy. Is calcium or cyclic AMP involved in the inhibitory effect on pituitary hormone secretion of the tripeptide aldehyde proteinase inhibitors? Mol. Cell. Endocrinol. 52: 63, 1987.
Fournier A., Wang Ch.-T., Felix A.M. Applications of BOP reagent in solid phase synthesis. Int. J. Pept. Prot. Res. 31: 86, 1988.
Rafferty B., Schulster D. Radioimmunoassay for human growth hormone-releasing factor (hGRF1–40): comparison of plasma immunoreactive GRF after intravenous and subcutaneous administration to rats. Mol. Cell. Endocrinol. 41: 19, 1985.
Pugsley L.I. The application of the principles of statistical analysis to the biological assay of hormones. Endocrinology 39: 161, 1946.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mezö, I., Kovács, M., Szöke, B. et al. New Gaba-containing analogues of human Growth Hormone-Releasing Hormone (1–30)-amide: I. Synthesis and in vitro biological activity. J Endocrinol Invest 16, 793–798 (1993). https://doi.org/10.1007/BF03348929
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348929